https://www.selleckchem.com/pr....oducts/cordycepin.ht
Incremental cost-effectiveness ratios (ICERs) were calculated over a lifetime horizon. A discount rate of 3.5% per year was applied to costs and benefits. Deterministic ICER was £46207 per quality-adjusted life year (QALY). Costs and utilities were £204022 and 3.27 QALYs for the LVAD arm vs. £77790 and 0.54 QALYs for the MM arm. Sensitivity analyses confirmed robustness of the primary analysis. The implantation of the HeartWare™ HVAD™ System in patients ineligible for cardiac transplantation as DT is a cost-effective therapy in the N
Like
Comment
Share
